Austrian drug maker’s restructuring succumbs to coronavirus pandemic

An Austrian drugs and medical equipment manufacturer, whose restructuring was being overseen by Stefan Riel, will now enter liquidation after investors pulled out of a capital increase citing the coronavirus pandemic’s impact on sales.

Unlock unlimited access to all Global Restructuring Review content